United Therapeutics (UTH) Ratios
United Therapeutics Ratios
DE:UTH's free cash flow for Q2 2026 was $205.60M. For the 2026 fiscal year, DE:UTH's free cash flow was decreased by $-108.00M and operating cash flow was $313.60M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.60 | 5.25 | 4.41 | 9.85 | 7.61 |
| Quick Ratio | 6.28 | 5.03 | 4.28 | 9.55 | 7.30 |
| Cash Ratio | 2.78 | 2.30 | 1.50 | 2.80 | 2.93 |
| Solvency Ratio | 1.81 | 1.38 | 0.88 | 0.62 | 0.43 |
| Operating Cash Flow Ratio | 2.78 | 1.80 | 1.22 | 2.34 | 1.96 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 4.42 | 2.44 | 0.00 | 0.00 |
| Net Current Asset Value | $ 2.92B | $ 2.95B | $ 2.37B | $ 2.13B | $ 1.11B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.04 | 0.10 | 0.13 | 0.15 |
| Debt-to-Equity Ratio | 0.01 | 0.05 | 0.12 | 0.17 | 0.20 |
| Debt-to-Capital Ratio | 0.01 | 0.04 | 0.10 | 0.14 | 0.17 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.05 | 0.14 | 0.17 |
| Financial Leverage Ratio | 1.11 | 1.14 | 1.20 | 1.26 | 1.31 |
| Debt Service Coverage Ratio | 73.84 | 3.82 | 2.39 | 25.22 | 33.26 |
| Interest Coverage Ratio | 77.81 | 32.10 | 19.98 | 30.24 | 29.89 |
| Debt to Market Cap | 0.00 | 0.02 | 0.07 | 0.06 | 0.08 |
| Interest Debt Per Share | 1.29 | 7.59 | 16.22 | 18.29 | 18.23 |
| Net Debt to EBITDA | -0.84 | -0.84 | -0.37 | -0.15 | -0.13 |
| Profitability Margins | |||||
| Gross Profit Margin | 87.92% | 89.24% | 88.94% | 92.42% | 92.73% |
| EBIT Margin | 54.46% | 54.98% | 57.30% | 51.08% | 40.75% |
| EBITDA Margin | 57.15% | 57.50% | 59.58% | 53.73% | 43.71% |
| Operating Profit Margin | 47.67% | 47.86% | 50.91% | 50.60% | 32.98% |
| Pretax Profit Margin | 53.85% | 53.49% | 54.75% | 49.09% | 35.24% |
| Net Profit Margin | 41.94% | 41.53% | 42.31% | 37.56% | 28.23% |
| Continuous Operations Profit Margin | 41.94% | 41.53% | 42.31% | 37.56% | 28.23% |
| Net Income Per EBT | 77.88% | 77.65% | 77.28% | 76.51% | 80.11% |
| EBT Per EBIT | 112.96% | 111.76% | 107.54% | 97.03% | 106.84% |
| Return on Assets (ROA) | 16.94% | 16.23% | 13.74% | 12.03% | 9.20% |
| Return on Equity (ROE) | 18.81% | 18.55% | 16.46% | 15.16% | 12.02% |
| Return on Capital Employed (ROCE) | 20.73% | 20.78% | 18.62% | 17.18% | 11.43% |
| Return on Invested Capital (ROIC) | 16.13% | 15.44% | 13.54% | 13.15% | 9.16% |
| Return on Tangible Assets | 17.19% | 16.48% | 13.96% | 12.12% | 9.28% |
| Earnings Yield | 6.18% | 7.49% | 9.57% | 5.75% | 4.90% |
| Efficiency Ratios | |||||
| Receivables Turnover | 9.09 | 10.30 | 8.35 | 8.79 | 8.48 |
| Payables Turnover | 54.14 | 51.62 | 45.98 | 35.78 | 32.24 |
| Inventory Turnover | 2.10 | 1.96 | 2.30 | 1.44 | 1.31 |
| Fixed Asset Turnover | 1.84 | 2.35 | 2.23 | 2.25 | 2.16 |
| Asset Turnover | 0.40 | 0.39 | 0.32 | 0.32 | 0.33 |
| Working Capital Turnover Ratio | 1.01 | 0.98 | 0.80 | 0.77 | 0.87 |
| Cash Conversion Cycle | 207.28 | 214.45 | 194.27 | 285.13 | 311.19 |
| Days of Sales Outstanding | 40.16 | 35.43 | 43.74 | 41.55 | 43.03 |
| Days of Inventory Outstanding | 173.86 | 186.09 | 158.47 | 253.78 | 279.49 |
| Days of Payables Outstanding | 6.74 | 7.07 | 7.94 | 10.20 | 11.32 |
| Operating Cycle | 214.02 | 221.52 | 202.21 | 295.33 | 322.51 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 35.24 | 29.36 | 20.90 | 17.64 | 13.32 |
| Free Cash Flow Per Share | 23.49 | 23.91 | 15.97 | 14.59 | 10.63 |
| Dividend Paid and CapEx Coverage Ratio | 3.00 | 5.38 | 4.24 | 5.78 | 4.95 |
| Capital Expenditure Coverage Ratio | 3.00 | 5.38 | 4.24 | 5.78 | 4.95 |
| Operating Cash Flow Coverage Ratio | 41.52 | 4.42 | 1.40 | 1.00 | 0.75 |
| Operating Cash Flow to Sales Ratio | 0.49 | 0.46 | 0.42 | 0.41 | 0.35 |
| Free Cash Flow Yield | 4.82% | 6.78% | 7.26% | 5.25% | 4.92% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 16.17 | 13.34 | 10.45 | 17.40 | 20.39 |
| Price-to-Sales (P/S) Ratio | 6.78 | 5.54 | 4.42 | 6.53 | 5.76 |
| Price-to-Book (P/B) Ratio | 3.04 | 2.47 | 1.72 | 2.64 | 2.45 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 20.74 | 14.76 | 13.77 | 19.06 | 20.32 |
| Price-to-Operating Cash Flow Ratio | 13.83 | 12.02 | 10.52 | 15.77 | 16.22 |
| Price-to-Earnings Growth (PEG) Ratio | 1.16 | 0.52 | 0.33 | 0.34 | -2.26 |
| Enterprise Value Multiple | 11.03 | 8.80 | 7.05 | 12.01 | 13.04 |
| Enterprise Value | 20.07B | 14.55B | 9.78B | 12.49B | 9.61B |
| EV to EBITDA | 11.03 | 8.80 | 7.05 | 12.01 | 13.04 |
| EV to Sales | 6.30 | 5.06 | 4.20 | 6.45 | 5.70 |
| EV to Free Cash Flow | 19.28 | 13.47 | 13.09 | 18.82 | 20.12 |
| EV to Operating Cash Flow | 12.85 | 10.96 | 10.00 | 15.57 | 16.06 |
| Tangible Book Value Per Share | 157.56 | 140.09 | 125.44 | 104.44 | 87.18 |
| Shareholders’ Equity Per Share | 160.19 | 142.57 | 127.88 | 105.42 | 88.17 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.22 | 0.22 | 0.23 | 0.23 | 0.20 |
| Revenue Per Share | 71.84 | 63.66 | 49.73 | 42.56 | 37.54 |
| Net Income Per Share | 30.13 | 26.44 | 21.04 | 15.98 | 10.60 |
| Tax Burden | 0.78 | 0.78 | 0.77 | 0.77 | 0.80 |
| Interest Burden | 0.99 | 0.97 | 0.96 | 0.96 | 0.86 |
| Research & Development to Revenue | 0.17 | 0.17 | 0.18 | 0.17 | 0.32 |
| SG&A to Revenue | 0.23 | 0.22 | 0.17 | 0.21 | 0.24 |
| Stock-Based Compensation to Revenue | 0.05 | 0.05 | 0.02 | 0.06 | 0.08 |
| Income Quality | 1.17 | 1.11 | 0.99 | 1.10 | 1.26 |
Currency in USD